Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 4/20 | 0.46 |
| ▸ | CTSL | P07711 | 4/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28171182 | 0.88 | MEN1 (0.47) | CTSVCTSLBACE1MEN1KMT2A | |
| SCHEMBL561090 | 0.85 | MAOB (0.56) | CTSVCTSLBACE1MEN1KMT2A | |
| SCHEMBL19327132 | 0.82 | MEN1 (0.45) | CTSVCTSLBACE1MEN1KMT2A | |
| SCHEMBL27585583 | 0.77 | CTSV (0.54) | CTSVCTSLBACE1MEN1KMT2A | |
| SCHEMBL11262742 | 0.76 | MAPT (0.54) | CTSVCTSLMEN1KMT2AMAPT | |
| SCHEMBL27684770 | 0.76 | BACE1 (0.52) | BACE1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL27647870 | 0.75 | MAPT (0.45) | BACE1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL1663438 | 0.75 | MEN1 (0.57) | CTSVCTSLBACE1MEN1KMT2A | |
| SCHEMBL30832846 | 0.75 | MEN1 (0.57) | CTSVCTSLBACE1MEN1KMT2A | |
| SCHEMBL5024079 | 0.75 | BACE1 (0.46) | BACE1MEN1KMT2AMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10059678-B2 | Process for preparing olodaterol and intermediates thereof | REDDY, G. Pratap (IN) | 2018-08-28 | — | — | US | disclosed |
| US-20170260149-A1 | A Process for Preparing Olodaterol and Intermediates Thereof | REDDY, G. Pratap (IN) | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260149-A1 | A Process for Preparing Olodaterol and Intermediates Thereof | CYP4A11, CYP11B1, CYP11B2 | CTSV 3994/4885CTSL 3028/4885BACE1 478/4885 |
| US-10059678-B2 | Process for preparing olodaterol and intermediates thereof | CYP4A11, CYP11B1, CYP11B2 | CTSV 4263/4885CTSL 3411/4885BACE1 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.